{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:29:58Z","timestamp":1793640598127,"version":"4.5.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s13300-026-01921-0","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T08:06:34Z","timestamp":1790582794000},"page":"1613-1638","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["New Amylin-Based Agonists for the Treatment of Obesity and Type\u00a02 Diabetes Mellitus"],"prefix":"10.1007","volume":"17","author":[{"given":"Theodoros","family":"Panou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanthia","family":"Gouveri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djordje S.","family":"Popovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7320-785X","authenticated-orcid":false,"given":"Nikolaos","family":"Papanas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"1921_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119","volume":"183","author":"H Sun","year":"2021","unstructured":"Sun H, Saeedi P, Karuranga S, et al. IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res Clin Pract. 2021;183:109119.","journal-title":"Diabetes Res Clin Pract"},{"key":"1921_CR2","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/S0140-6736(25)00355-1","volume":"405","author":"GBD 2021 Adult BMI Collaborators","year":"2025","unstructured":"GBD 2021 Adult BMI Collaborators. Global, regional, and national prevalence of adult overweight and obesity, 1990\u20132021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. Lancet. 2025;405:813\u201338.","journal-title":"Lancet"},{"issue":"Suppl 1","key":"1921_CR3","doi-asserted-by":"publisher","first-page":"S183","DOI":"10.2337\/dc26-S009","volume":"49","author":"American Diabetes Association Professional Practice Committee for Diabetes","year":"2026","unstructured":"American Diabetes Association Professional Practice Committee for Diabetes. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes-2026. Diabetes Care. 2026;49(Suppl 1):S183\u2013215.","journal-title":"Diabetes Care"},{"key":"1921_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S2213-8587(24)00316-4","volume":"13","author":"F Rubino","year":"2025","unstructured":"Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13:221\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1921_CR5","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1016\/S0140-6736(25)02105-1","volume":"407","author":"MA Nauck","year":"2026","unstructured":"Nauck MA, Tuttle KR, Tsch\u00f6p MH, Bl\u00fcher M. Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. Lancet. 2026;407:892\u2013908.","journal-title":"Lancet"},{"key":"1921_CR6","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2337\/dci24-0003","volume":"47","author":"DJ Drucker","year":"2024","unstructured":"Drucker DJ. Efficacy and safety of GLP-1 medicines for type\u00a02 diabetes and obesity. Diabetes Care. 2024;47:1873\u201388.","journal-title":"Diabetes Care"},{"key":"1921_CR7","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1038\/s41573-025-01183-8","volume":"24","author":"DJ Drucker","year":"2025","unstructured":"Drucker DJ. GLP-1-based therapies for diabetes, obesity and beyond. Nat Rev Drug Discov. 2025;24:631\u201350.","journal-title":"Nat Rev Drug Discov"},{"key":"1921_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1210\/endrev\/bnaf036","volume":"47","author":"JW Son","year":"2026","unstructured":"Son JW, le Roux CW, Bl\u00fcher M, Nauck MA, Lim S. Novel GLP-1-based medications for type\u00a02 diabetes and obesity. Endocr Rev. 2026;47:159\u201377. https:\/\/doi.org\/10.1210\/endrev\/bnaf036.","journal-title":"Endocr Rev"},{"key":"1921_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1056\/NEJMoa2107519","volume":"385","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type\u00a02 diabetes. N Engl J Med. 2021;385:503\u201315.","journal-title":"N Engl J Med"},{"key":"1921_CR10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2600751","author":"CW le Roux","year":"2026","unstructured":"le Roux CW, Wharton S, Startseva E, et al. Survodutide once weekly for the treatment of adults with obesity. N Engl J Med. 2026. https:\/\/doi.org\/10.1056\/nejmoa2600751.","journal-title":"N Engl J Med"},{"key":"1921_CR11","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41586-025-10026-w","volume":"652","author":"D Zhu","year":"2026","unstructured":"Zhu D, Zhao J, Cai H, et al. Mazdutide versus placebo in Chinese adults with type\u00a02 diabetes. Nature. 2026;652:174\u201380.","journal-title":"Nature"},{"key":"1921_CR12","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1016\/S0140-6736(26)00967-0","volume":"407","author":"HS Bajaj","year":"2026","unstructured":"Bajaj HS, Welch M, Shah P, et al. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type\u00a02 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase\u00a03 trial. Lancet. 2026;407:2402\u201313.","journal-title":"Lancet"},{"key":"1921_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2020.101109","volume":"46","author":"N Sonne","year":"2021","unstructured":"Sonne N, Karsdal MA, Henriksen K. Mono and dual agonists of the amylin, calcitonin, and CGRP receptors and their potential in metabolic diseases. Mol Metab. 2021;46:101109.","journal-title":"Mol Metab"},{"key":"1921_CR14","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1038\/s41574-025-01125-9","volume":"21","author":"CS Walker","year":"2025","unstructured":"Walker CS, Aitken JF, Vazhoor Amarsingh G, Zhang S, Cooper GJS. Amylin: emergent therapeutic opportunities in overweight, obesity and diabetes mellitus. Nat Rev Endocrinol. 2025;21:482\u201394.","journal-title":"Nat Rev Endocrinol"},{"key":"1921_CR15","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s42255-026-01465-4","volume":"8","author":"A Secher","year":"2026","unstructured":"Secher A, Lutz TA, Raun K. The story of amylin: from physiology to therapy. Nat Metab. 2026;8:299\u2013312.","journal-title":"Nat Metab"},{"key":"1921_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/S0140-6736(25)01176-6","volume":"406","author":"A Gasiorek","year":"2025","unstructured":"Gasiorek A, Heydorn A, Gabery S, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase\u00a01, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406:135\u201348.","journal-title":"Lancet"},{"key":"1921_CR17","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0140-6736(25)01185-7","volume":"406","author":"K Dahl","year":"2025","unstructured":"Dahl K, Toubro S, Dey S, et al. Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase\u00a01b\/2a randomised controlled study. Lancet. 2025;406:149\u201362.","journal-title":"Lancet"},{"key":"1921_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2026.156594","volume":"179","author":"L Fu","year":"2026","unstructured":"Fu L, Ding R, Xu G, Hu J, Yang P. Amycretin in obesity: mechanisms, clinical efficacy, and future perspectives. Metabolism. 2026;179:156594.","journal-title":"Metabolism"},{"key":"1921_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2025.102271","volume":"102","author":"DA Briere","year":"2025","unstructured":"Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept. Mol Metab. 2025;102:102271.","journal-title":"Mol Metab"},{"key":"1921_CR20","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1111\/dom.70439","volume":"28","author":"S Bhattachar","year":"2026","unstructured":"Bhattachar S, Tham LS, Tidemann-Miller B, et al. Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: phase\u00a01 proof of concept. Diabetes Obes Metab. 2026;28:2651\u201360.","journal-title":"Diabetes Obes Metab"},{"key":"1921_CR21","doi-asserted-by":"publisher","first-page":"2631","DOI":"10.1016\/S0140-6736(25)02155-5","volume":"406","author":"LK Billings","year":"2025","unstructured":"Billings LK, Hsia S, Bays H, et al. Eloralintide, a selective amylin receptor agonist for the treatment of obesity: a 48-week phase\u00a02, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2025;406:2631\u201343.","journal-title":"Lancet"},{"key":"1921_CR22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1056\/NEJMoa2502081","volume":"393","author":"WT Garvey","year":"2025","unstructured":"Garvey WT, Bl\u00fcher M, Osorto Contreras CK, et al. Coadministered cagrilintide and semaglutide in adults with overweight or obesity. N Engl J Med. 2025;393:635\u201347.","journal-title":"N Engl J Med"},{"key":"1921_CR23","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1056\/NEJMoa2502082","volume":"393","author":"MJ Davies","year":"2025","unstructured":"Davies MJ, Bajaj HS, Broholm C, et al. Cagrilintide-semaglutide in adults with overweight or obesity and type\u00a02 diabetes. N Engl J Med. 2025;393:648\u201359.","journal-title":"N Engl J Med"},{"key":"1921_CR24","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1016\/S2213-8587(26)00125-7","volume":"14","author":"JB Buse","year":"2026","unstructured":"Buse JB, Bajaj HS, Dalskov SM, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type\u00a02 diabetes (REIMAGINE\u00a02): a double-blind, randomised, controlled, phase\u00a03 study. Lancet Diabetes Endocrinol. 2026;14:662\u201377.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1921_CR25","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S2213-8587(26)00126-9","volume":"14","author":"VR Aroda","year":"2026","unstructured":"Aroda VR, Buzzetti R, Dalskov SM, et al. Efficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type\u00a02 diabetes inadequately controlled on diet and exercise (REIMAGINE\u00a01): a randomised, double-blind, placebo-controlled, phase\u00a03a study. Lancet Diabetes Endocrinol. 2026;14:649\u201361.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1921_CR26","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/S0140-6736(26)01022-6","volume":"408","author":"J Rosenstock","year":"2026","unstructured":"Rosenstock J, Billings LK, Gajria R, et al. Cagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type\u00a02 diabetes (REIMAGINE\u00a03): a randomised, double-blind, placebo-controlled, multicentre, phase\u00a03 study. Lancet. 2026;408:38\u201351.","journal-title":"Lancet"},{"key":"1921_CR27","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/S2213-8587(25)00402-4","volume":"14","author":"T Yamauchi","year":"2026","unstructured":"Yamauchi T, Becker NP, Hagemann CA, et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type\u00a02 diabetes in Japan and Taiwan (REDEFINE\u00a05): a multicentre, randomised, active-controlled, phase\u00a03a trial. Lancet Diabetes Endocrinol. 2026;14:450\u201362.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1921_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.appet.2022.105965","volume":"172","author":"TA Lutz","year":"2022","unstructured":"Lutz TA. Creating the amylin story. Appetite. 2022;172:105965.","journal-title":"Appetite"},{"key":"1921_CR29","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1152\/physrev.00042.2009","volume":"91","author":"P Westermark","year":"2011","unstructured":"Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev. 2011;91:795\u2013826.","journal-title":"Physiol Rev"},{"key":"1921_CR30","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1124\/pr.115.010629","volume":"67","author":"DL Hay","year":"2015","unstructured":"Hay DL, Chen S, Lutz TA, Parkes DG, Roth JD. Amylin: pharmacology, physiology, and clinical potential. Pharmacol Rev. 2015;67:564\u2013600.","journal-title":"Pharmacol Rev"},{"key":"1921_CR31","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/BF00401833","volume":"38","author":"AA Young","year":"1995","unstructured":"Young AA, Gedulin B, Vine W, Percy A, Rink TJ. Gastric emptying is accelerated in diabetic BB rats and is slowed by subcutaneous injections of amylin. Diabetologia. 1995;38:642\u20138.","journal-title":"Diabetologia"},{"key":"1921_CR32","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1016\/j.cmet.2015.10.012","volume":"22","author":"Z Li","year":"2015","unstructured":"Li Z, Kelly L, Heiman M, Greengard P, Friedman JM. Hypothalamic amylin acts in concert with leptin to regulate food intake. Cell Metab. 2015;22:1059\u201367.","journal-title":"Cell Metab"},{"key":"1921_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s11892-015-0693-3","volume":"16","author":"T Jorsal","year":"2016","unstructured":"Jorsal T, Rungby J, Knop FK, Vilsb\u00f8ll T. GLP-1 and amylin in the treatment of obesity. Curr Diab Rep. 2016;16:1.","journal-title":"Curr Diab Rep"},{"key":"1921_CR34","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/j.1476-5381.2011.01537.x","volume":"166","author":"JD Roth","year":"2012","unstructured":"Roth JD, Erickson MR, Chen S, Parkes DG. GLP-1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities. Br J Pharmacol. 2012;166:121\u201336.","journal-title":"Br J Pharmacol"},{"key":"1921_CR35","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1055\/s-2005-837662","volume":"113","author":"R Ratner","year":"2005","unstructured":"Ratner R, Whitehouse F, Fineman MS, et al. Adjunctive therapy with pramlintide lowers HbA1c without concomitant weight gain and increased risk of severe hypoglycemia in patients with type\u00a01 diabetes approaching glycemic targets. Exp Clin Endocrinol Diabetes. 2005;113:199\u2013204.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"1921_CR36","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.2337\/dc06-0042","volume":"29","author":"S Edelman","year":"2006","unstructured":"Edelman S, Garg S, Frias J, et al. A double-blind, placebo-controlled trial assessing pramlintide treatment in the setting of intensive insulin therapy in type\u00a01 diabetes. Diabetes Care. 2006;29:2189\u201395.","journal-title":"Diabetes Care"},{"key":"1921_CR37","doi-asserted-by":"publisher","first-page":"66504","DOI":"10.18632\/oncotarget.16008","volume":"8","author":"YC Qiao","year":"2017","unstructured":"Qiao YC, Ling W, Pan YH, et al. Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type\u00a01 diabetes mellitus: a systematic review and meta-analysis. Oncotarget. 2017;8:66504\u201315.","journal-title":"Oncotarget"},{"key":"1921_CR38","doi-asserted-by":"publisher","first-page":"724","DOI":"10.2337\/diacare.25.4.724","volume":"25","author":"F Whitehouse","year":"2002","unstructured":"Whitehouse F, Kruger DF, Fineman M, et al. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type\u00a01 diabetes. Diabetes Care. 2002;25:724\u201330.","journal-title":"Diabetes Care"},{"key":"1921_CR39","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.4158\/EP13477.OR","volume":"20","author":"K Herrmann","year":"2014","unstructured":"Herrmann K, Shan K, Brunell SC, Chen S. Effects of pramlintide in patients with type\u00a02 diabetes mellitus: an analysis using daily insulin dose tertiles. Endocr Pract. 2014;20:1070\u20135.","journal-title":"Endocr Pract"},{"key":"1921_CR40","doi-asserted-by":"publisher","first-page":"987","DOI":"10.2337\/diacare.21.6.987","volume":"21","author":"RG Thompson","year":"1998","unstructured":"Thompson RG, Pearson L, Schoenfeld SL, Kolterman OG. Pramlintide, a synthetic analog of human amylin, improves the metabolic profile of patients with type\u00a02 diabetes using insulin. The Pramlintide in Type\u00a02 Diabetes Group. Diabetes Care. 1998;21:987\u201393.","journal-title":"Diabetes Care"},{"key":"1921_CR41","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1046\/j.1463-1326.2003.00295.x","volume":"5","author":"P Hollander","year":"2003","unstructured":"Hollander P, Ratner R, Fineman M, et al. Addition of pramlintide to insulin therapy lowers HbA1c in conjunction with weight loss in patients with type\u00a02 diabetes approaching glycaemic targets. Diabetes Obes Metab. 2003;5:408\u201314.","journal-title":"Diabetes Obes Metab"},{"key":"1921_CR42","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.2337\/dc07-0589","volume":"30","author":"M Riddle","year":"2007","unstructured":"Riddle M, Frias J, Zhang B, et al. Pramlintide improved glycemic control and reduced weight in patients with type\u00a02 diabetes using basal insulin. Diabetes Care. 2007;30:2794\u20139.","journal-title":"Diabetes Care"},{"key":"1921_CR43","doi-asserted-by":"publisher","first-page":"784","DOI":"10.2337\/diacare.26.3.784","volume":"26","author":"PA Hollander","year":"2003","unstructured":"Hollander PA, Levy P, Fineman MS, et al. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type\u00a02 diabetes: a 1-year randomized controlled trial. Diabetes Care. 2003;26:784\u201390.","journal-title":"Diabetes Care"},{"key":"1921_CR44","first-page":"203","volume":"2","author":"G Ryan","year":"2009","unstructured":"Ryan G, Briscoe TA, Jobe L. Review of pramlintide as adjunctive therapy in treatment of type\u00a01 and type\u00a02 diabetes. Drug Des Devel Ther. 2009;2:203\u201314.","journal-title":"Drug Des Devel Ther"},{"key":"1921_CR45","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1210\/jc.2006-2003","volume":"92","author":"L Aronne","year":"2007","unstructured":"Aronne L, Fujioka K, Aroda V, et al. Progressive reduction in body weight after treatment with the amylin analog pramlintide in obese people: a phase\u00a02, randomized, placebo-controlled, dose-escalation study. J Clin Endocrinol Metab. 2007;92:2977\u201383.","journal-title":"J Clin Endocrinol Metab"},{"key":"1921_CR46","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1463-1326.2010.01337.x","volume":"13","author":"D Singh-Franco","year":"2011","unstructured":"Singh-Franco D, Perez A, Harrington C. The effect of pramlintide acetate on glycemic control and weight in patients with type\u00a02 diabetes mellitus and in obese patients without diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2011;13:169\u201380.","journal-title":"Diabetes Obes Metab"},{"key":"1921_CR47","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1124\/jpet.121.000567","volume":"377","author":"MM Fletcher","year":"2021","unstructured":"Fletcher MM, Keov P, Truong TT, et al. AM833 is a novel agonist of calcitonin family g protein-coupled receptors: pharmacological comparison with six selective and nonselective agonists. J Pharmacol Exp Ther. 2021;377:417\u201340.","journal-title":"J Pharmacol Exp Ther"},{"key":"1921_CR48","doi-asserted-by":"publisher","first-page":"11183","DOI":"10.1021\/acs.jmedchem.1c00565","volume":"64","author":"T Kruse","year":"2021","unstructured":"Kruse T, Hansen JL, Dahl K, et al. Development of cagrilintide, a long-acting amylin analogue. J Med Chem. 2021;64:11183\u201394.","journal-title":"J Med Chem"},{"key":"1921_CR49","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1038\/s41591-026-04386-7","volume":"32","author":"LJ Aronne","year":"2026","unstructured":"Aronne LJ, Horn DB, le Roux CW, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase\u00a03b ATTAIN-MAINTAIN trial. Nat Med. 2026;32:2679\u201387.","journal-title":"Nat Med"},{"key":"1921_CR50","doi-asserted-by":"publisher","first-page":"4818","DOI":"10.1111\/dom.70666","volume":"28","author":"N Eisa","year":"2026","unstructured":"Eisa N, Barood O. Lean mass changes with incretin therapy versus lifestyle intervention: a systematic review and meta-analysis of randomised controlled trials. Diabetes Obes Metab. 2026;28:4818\u201327.","journal-title":"Diabetes Obes Metab"},{"key":"1921_CR51","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s11154-025-09967-4","volume":"26","author":"DH Ryan","year":"2025","unstructured":"Ryan DH. New drugs for the treatment of obesity: do we need approaches to preserve muscle mass? Rev Endocr Metab Disord. 2025;26:805\u201313.","journal-title":"Rev Endocr Metab Disord"},{"key":"1921_CR52","doi-asserted-by":"publisher","DOI":"10.1161\/HYPERTENSIONAHA.125.26055","volume":"83","author":"S Verma","year":"2026","unstructured":"Verma S, B\u00f6ttcher M, Brown P, et al. CagriSema reduces blood pressure in adults with overweight or obesity: REDEFINE\u00a01. Hypertension. 2026;83:e26055.","journal-title":"Hypertension"},{"key":"1921_CR53","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1016\/S0140-6736(25)01776-3","volume":"406","author":"MHA Muskiet","year":"2026","unstructured":"Muskiet MHA, Nardone M, Rensen PCN, Cherney DZI, Cooper ME. Amylin and the renin-angiotensin system: risk or opportunity in amylin-based therapy? Lancet. 2026;406:2980\u20133.","journal-title":"Lancet"},{"key":"1921_CR54","doi-asserted-by":"crossref","unstructured":"Ceriello A, Prattichizzo F, Mastan Sheik Abdullah AR, et al. Causes and consequences of discontinuation of GLP1RAs or tirzepatide. Nat Rev Endocrinol. 2026;22(9):530\u201342.","DOI":"10.1038\/s41574-026-01258-5"},{"key":"1921_CR55","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1093\/cvr\/cvae120","volume":"120","author":"AF Lubberding","year":"2024","unstructured":"Lubberding AF, Veedfald S, Achter JS, et al. Glucagon-like peptide-1 increases heart rate by a direct action on the sinus node. Cardiovasc Res. 2024;120:1427\u201341.","journal-title":"Cardiovasc Res"},{"key":"1921_CR56","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1785129","volume":"17","author":"D Chen","year":"2026","unstructured":"Chen D, Wang Z, Xie Z, Chen Y, Luo S, Xu S. Cardiovascular adverse event reporting profile of tirzepatide: a real-world pharmacovigilance analysis of heart failure, arrhythmias, and ischemic events. Front Pharmacol. 2026;17:1785129.","journal-title":"Front Pharmacol"},{"key":"1921_CR57","doi-asserted-by":"publisher","first-page":"5805","DOI":"10.1111\/dom.15951","volume":"26","author":"MBN Gabe","year":"2024","unstructured":"Gabe MBN, Fuhr R, Sinn A, et al. Cagrilintide is not associated with clinically relevant QTc prolongation: a thorough QT study in healthy participants. Diabetes Obes Metab. 2024;26:5805\u201311.","journal-title":"Diabetes Obes Metab"},{"key":"1921_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105862","volume":"118","author":"RE Kuhre","year":"2025","unstructured":"Kuhre RE, Ballar\u00edn-Gonz\u00e1lez B, Brand CL, et al. The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats. EBioMedicine. 2025;118:105862.","journal-title":"EBioMedicine"},{"key":"1921_CR59","doi-asserted-by":"publisher","DOI":"10.1210\/jcemcr\/luad040","volume":"1","author":"G Wong","year":"2023","unstructured":"Wong G, Garner EM, Srivastava G. Combined GLP-1 receptor agonist and amylin analogue pharmacotherapy to treat obesity comorbid with type\u00a01 diabetes. JCEM Case Rep. 2023;1:luad040.","journal-title":"JCEM Case Rep"}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01921-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01921-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-026-01921-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T17:02:28Z","timestamp":1793638948000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-026-01921-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":59,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["1921"],"URL":"https:\/\/doi.org\/10.1007\/s13300-026-01921-0","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"28 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Theodoros Panou has nothing to disclose. Evanthia Gouveri has attended conferences sponsored by Berlin-Chemie, Sanofi, AstraZeneca, Novo Nordisk, Lilly and Boehringer Ingelheim; received speaker honoraria by Boehringer Ingelheim, Sanofi and Menarini. Djordje S. Popovic declares associations with Abbott, Alkaloid, Amicus, AstraZeneca, Boehringer Ingelheim, Berlin-Chemie, Eli Lilly, Galenika, Krka, Merck, Novo Nordisk, PharmaSwiss, Sanofi-Aventis, Servier, Viatris, and W\u00f6rwag Pharma. Nikolaos Papanas has been an advisory board member of AstraZeneca, Bayer, Boehringer Ingelheim, Menarini, MSD, Novo Nordisk, Pfizer, Takeda and TrigoCare International; has participated in sponsored studies by AstraZeneca, Eli Lilly, GSK, MSD, Novo Nordisk, Novartis and Sanofi-Aventis; has received honoraria as a speaker for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Elpen, KRKA, Menarini, MSD, Mylan, Novo Nordisk, Pfizer, Roche, Sanofi-Aventis and Vianex; and has attended conferences sponsored by TrigoCare International, Eli Lilly, Galenica, Menarini, Novo Nordisk, Pfizer and Sanofi-Aventis. Nikolaos Papanas is an Editorial Board member of\n                      Diabetes Therapy\n                      . Nikolaos Papanas was not involved in the selection of peer reviewers for the manuscript or any of the subsequent editorial decisions.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}